• Onset: 30-90 min after oral dose (Tmax ~1-2 hr after 500 mg oral, ~78% bioavailability).
• Peak: 2-4 hours; effect on metabolism takes 2-7 days to fully manifest as tissue carnitine drops.
• Character: subtle. Most users report nothing acutely on a single dose. After 1-2 weeks of daily use:
  • Mild reduction in perceived fatigue during sub-maximal cardio (the "gas tank" feel)
  • Slightly lower lactate accumulation at threshold work
  • Mild increase in resting alertness (peripheral; the GBB-NO axis vasodilation may explain this)
  • Not a felt stimulant — no euphoria, no jitteriness, no acute cognitive lift.
• Variability: healthy young trained athletes report the smallest effect (their endogenous metabolic flexibility already covers most of what meldonium delivers); ischemic patients and altitude-exposed users report the largest. For a 20yo MMA athlete with intact mitochondria, expect minimal subjective signal.
• Negative profile: rare GI upset, mild headache in week 1-2, occasional sleep onset delay if dosed late. Some users report a vague "warmth" or peripheral flushing (NO/vasodilation).

• Tolerance: minimal at standard doses — the pharmacology is substrate-depletion rather than receptor-targeting, so receptor downregulation does not apply.
• Diminishing returns: carnitine tissue depletion plateaus around 4-6 weeks; further dosing produces no additional metabolic shift.
• Recommended cycle: 2-4 weeks on / 4-8 weeks off was the Soviet-era convention. Continuous use produces no benefit beyond plateau and would prolong the WADA detection window indefinitely.
• Reset protocol: plasma clears in ~3-5 half-lives (~24-30 hours for plasma), but muscle and cardiac carnitine take 2-4 weeks to normalize; urinary detection persists ≥ 4 weeks (and in chronic users ≥ 60-90 days per Görgens 2016).

Theoretically synergistic

• L-carnitine / ALCAR: paradoxical — meldonium blocks carnitine synthesis and uptake; supplementing carnitine partially defeats the mechanism. Some Eastern European protocols pair them deliberately to target tissue-specific effects (heart only, sparing skeletal muscle), but this is highly empirical and not well validated.
• Coenzyme Q10: supports the same mitochondrial efficiency goal via a different mechanism (electron transport chain). Plausible synergy; no published data.
• Trimetazidine (another fatty-acid oxidation inhibitor, 3-KAT inhibitor — also S4.5.1 banned): mechanistically overlapping; sometimes co-prescribed in Russian cardiology. For tested athletes: stacking two banned cardio-metabolic modulators is twice the regulatory exposure.
• MOTS-c: mitochondrial peptide that increases AMPK signaling and improves metabolic flexibility — plausible synergy on the "metabolic flexibility under stress" axis; no published combination data and MOTS-c is itself research-chem only.
• ITPP (myo-inositol trispyrophosphate): allosteric Hb modulator that increases tissue O₂ release — mechanistically complementary (meldonium reduces O₂ demand per ATP, ITPP increases O₂ supply). WADA-banned (S2.2 erythropoiesis-receptor agonist family by analogy). No clinical data on the combination.

Avoid stacking with

• Insulin / sulfonylureas / GLP-1 agonists (high-dose) — additive glucose-lowering; hypoglycemia risk.
• Cardiac glycosides (digoxin) — theoretical interaction on sodium-potassium ATPase pathways; limited data.
• Other fatty-acid oxidation inhibitors (trimetazidine, ranolazine, perhexiline) — additive metabolic shift, unclear safety.

Neutral

• Standard supplementation (Mg, omega-3, creatine, B-vitamins) — no known interactions.
• Most peptides (BPC-157, TB-500, semax, selank) — no known interactions, different mechanisms.

• Insulin / oral hypoglycemics: additive hypoglycemia risk. Monitor glucose if combined.
• Nitrates (nitroglycerin, isosorbide): theoretical additive vasodilation (both increase NO availability). Modest risk of orthostatic hypotension.
• Nephrotoxic drugs (NSAIDs chronic, aminoglycosides, certain contrast agents): renal clearance is the only meaningful elimination route — concurrent use that compromises renal function will prolong meldonium half-life.
• CYP enzymes: meldonium does not significantly induce or inhibit CYPs; PK interactions via this pathway are not expected.
• Anticoagulants: no documented interaction.

BBOX1 (γ-butyrobetaine hydroxylase)

• Polymorphisms in BBOX1 modulate baseline carnitine biosynthesis. Loss-of-function variants are rare and clinically severe; common polymorphisms (e.g., rs6772068) modestly reduce carnitine biosynthesis. In carriers of reduced-activity BBOX1 variants, meldonium's effect would be attenuated (less to inhibit) or amplified (already-low carnitine reaches deficiency threshold sooner). Direction depends on baseline.

SLC22A5 (OCTN2)

• The transporter meldonium competes with. Loss-of-function = primary carnitine deficiency (rare, severe). Heterozygous variants (~1-2% population) reduce tissue carnitine uptake and would make meldonium-induced depletion more pronounced. Combat athletes with even partial OCTN2 dysfunction could see exaggerated cardiac carnitine drop on standard doses — theoretical concern, no published case reports.

TMLHE / BBOX1 upstream

• The lysine → trimethyl-lysine → GBB pathway. Variants affecting upstream flux would modulate baseline carnitine and meldonium response.

For users in this archetype: when 23andMe results land (June 2026), parsing BBOX1 and SLC22A5 status would inform meldonium response if the user were considering it. He is not — WADA controls this — so this is genetic background information rather than a decision input.

Verification: for any source, plasma or urinary meldonium can be assayed by reference labs (Sports Medicine Research and Testing Laboratory in Salt Lake City; INRS in Quebec; the WADA-accredited European labs all run it). Cost ~$200-400/sample. Effectively useless for self-verification before consumption (you'd need to dose first), but useful if checking a supply for adulteration via dose-response on a single test pill.

For users in this archetype: not recommended at any sourcing tier. The WADA hard-block dominates. If hypothetically that constraint were absent, Grindeks Mildronate from a Russian or Latvian licensed pharmacy is the only sourcing path that produces a known-quantity, known-purity dose; everything else carries authentication risk.

Baseline (before starting — if hypothetically using)

• Free + total carnitine, acylcarnitine panel (plasma) — baseline carnitine status; predicts magnitude of depletion effect.
• Urinary carnitine, urinary GBB — baseline excretion; meldonium will increase carnitine excretion ~2-3× and GBB excretion ~3-4×.
• Fasting glucose + HbA1c — substrate-shift relevance; baseline metabolic health.
• Lactate (resting and at submaximal workload) — meldonium reduces lactate at threshold work; this is a sensitive efficacy biomarker.
• Lipid panel — secondary outcome; meldonium has modest effect on triglycerides via reduced fatty-acid metabolism.
• ECG resting + stress — baseline cardiac function; ischemia-tolerance benefit is the strongest indication.
• BP resting (3-day morning average) — meldonium tends to reduce BP modestly via NO-mediated vasodilation.
• Body composition (DEXA) — fatty-acid oxidation reduction has theoretical implications for fat-loss difficulty; weight-class athletes care about this.
• VO2max — endurance baseline; small but measurable improvement (3-7%) in untrained subjects.
• Renal function (BUN, creatinine, eGFR) — predicts elimination half-life and accumulation risk.
• hs-CRP — inflammatory baseline.

During use (hypothetical, for n=1 self-experiment)

• Free carnitine every 2 weeks — tracks depletion magnitude.
• Urinary GBB monthly — confirms BBOX1 inhibition (rises ~3-4×).
• Subjective endurance VAS daily for 4 weeks — primary efficacy signal.
• Lactate at fixed workload weekly — objective performance proxy.
• BP + HR monthly.

Post-cycle

• Free carnitine + urinary carnitine at 4 weeks off-cycle — confirms washout (should normalize within 4-6 weeks).
• WADA detection caveat: if user is or may become tested, urinary meldonium detection extends ≥ 4 weeks for low-dose use and ≥ 60-90 days for chronic use. The absence of meldonium in your bloodstream subjectively says nothing about whether a WADA-accredited lab can still detect a metabolite.